Roche trumpets data for Soliris rival in NMOSD after US, EU filingsRoche has continued to build the case for satralizumab, its experimental therapy for rare disease neuromyelitis optica spectrum Share XRoche trumpets data for Soliris rival in NMOSD after US, EU filingshttps://pharmaphorum.com/news/roche-trumpets-data-for-soliris-rival-in-nmosd-after-us-eu-filings/
Roche preps filings for satralizumab in rare disease NMOSDRoche is two for two in its phase 3 trials programme for satralizumab in the rare disease neuromyelitis Share XRoche preps filings for satralizumab in rare disease NMOSDhttps://pharmaphorum.com/news/roche-preps-filings-for-satralizumab-in-rare-disease-nmosd/
